Dysregulated inflammation is one of the hallmarks of cancer initiation and progression. Emerging evidence indicates that inflammasomes play a central role in regulating immune cell functions in various infections and cancer. Inflammasomes are multimeric complexes consisting of nucleotide-binding oligomerization domain (NOD) -like receptors (NLRs). Among the NLRs, NOD1, NOD2 and NLRP3 respond to a variety of endogenous (i.e. damage-associated molecular patterns) and exogenous (i.e. pathogen-associated molecular patterns) stimuli. The NLRP3 inflammasome is associated with the onset and progression of autoinflammatory and autoimmune diseases, including metabolic disorders, multiple sclerosis, inflammatory bowel disease, and cryopyrin-associated periodic fever syndrome. NLRP3 is also associated with a wide variety of infections and tumorigenesis that are closely correlated with chemotherapy response and prognosis. In this review, we explore the rapidly expanding body of research on the expression and functions of NLRP3 in infections and cancers and outline novel inhibitors targeting the NLRP3 inflammasome that could be developed as therapeutic alternatives to current anticancer treatment.
Introduction
The innate immune system deploys germline-encoded pattern-recognition receptors (PRRs) to sense molecular patterns from microorganisms and damaged cells, and initially detect microbes. These PRRs recognize microbespecific molecular signatures known as pathogen-associated molecular patterns (PAMPs) 1 and self-derived molecules from damaged cells known as damage-associated molecular patterns (DAMPs). 2, 3 In the last 20 years, several PRRs have been discovered, and their indispensable role in protecting hosts from pathogens is well studied. These PRRs include members of the toll-like receptors (TLRs), [4] [5] [6] nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs), 7, 8 retinoic acidinducible gene-I-like receptors (RLRs), 9 C-type lectin receptors, 10 and absent in melanoma (AIM2)-like receptors families. 11, 12 In addition to TLR family members that detect PAMPs, either on the cell surface or in the lumen of intracellular vesicles (e.g. endosomes or lysosomes), a cytosolic system that detects intracellular PAMPS has been demonstrated by studies in the last decade. These cytosolic PRRs include RLRs and NLRs. RLRs belong to a family of RNA helicases that specifically detect RNA species derived from viruses in the cytoplasm and coordinate antiviral Abbreviations: AIM2, absent in melanoma; AOM-DSS, azoxymethane-dextran sodium sulfate; ASC, apoptosis-associated specklike protein containing a CARD; DAMPs, damage-associated molecular patterns; IL-1b, interleukin-1b; IRGB10, interferon-inducible protein immunity-related GTPase family member b10; MDSCs, myeloid-derived suppressor cells; NLRs, nucleotide-binding oligomerization domain-like receptors; NOD, nucleotide-binding oligomerization domain; PAMPs, pathogen-associated molecular patterns; PRRs, pattern-recognition receptors; RLRs, retinoic acid-inducible gene-I-like receptors; ROS, reactive oxygen species; TAK1, transforming growth factor-b-activated kinase; TLRs, toll-like receptors; WT, wild-type; ZBP1/DAI, Z-DNA-binding protein 1/DNA-dependent activator of interferon regulatory factors
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programs by inducing type-I interferon. 13 NLRs constitute a large family of intracellular PRRs, several of which are well characterized, such as NOD1, NOD2 and NALP3/NLRP3. 8, 14 Cytosolic NLRs are associated with human diseases, including infections, cancer, and autoimmune and inflammatory disorders. These NLRs regulate inflammatory mechanisms by inducing cytokines, chemokines and antimicrobial genes. Upon activation, some NLRs form multiprotein complexes termed inflammasomes, whereas others mediate caspase-independent nuclear factor-jB and mitogen-activated protein kinase signaling. Moreover, NLRs and their downstream signaling components engage in intricate cross-talk between the cell death and autophagy pathways, 15 both of which are crucial processes for tumorigenesis. Because NLRs actively help regulate proinflammatory signals and recruit the adaptive arm of the immune system, defective NLR functions may lead to dysregulation of microbial sensing, which influences disease outcomes and tumorigenesis. 16 Increasing evidence suggests that chronic inflammation caused by aberrant NLR signaling is a powerful driver of tumorigenesis, whereby it abets genetic mutations, tumor growth and progression. Five PRRs (NLRP1, NLRP3, NLRC4, pyrin and AIM2) form inflammasomes. 17, 18 Emerging evidence indicates that several other members of the NLR family and the PYHIN family, including NLRP6, NLRP7, NLRP12 and IFI16, can also form inflammasomes, but their composition remains obscure. 18 Among these inflammasomes, the NLRP3 inflammasome has been under intensive investigation because of its possible involvement in several human diseases. In this review, we explore the rapidly expanding research on the expression and functions of NLRP3 in infections and cancers. We also outline novel approaches targeting NLRP3 signaling that could be developed as therapeutic alternatives to current anticancer treatment.
NLRP3 inflammasome in various infections
NLRP3 is a well-studied member of the NLR family. Its basal expression is not sufficient for inflammasome activation in resting cells and requires a two-checkpoint activation mechanism: a priming step and a second activation step that can be induced by various triggers (Table 1) . [19] [20] [21] [22] The NLRP3 inflammasome is assumed to sense disturbances in cellular homeostasis rather than directly recognize common motifs for its activation. Multiple cellular signals that have divergent molecular characteristics can trigger NLRP3 activation. Some well-known activators include crystalline substances (e.g. asbestos, silica or alum), host-derived DAMPs (e.g. uric acid or cholesterol crystals), lysosomal damage, potassium efflux, increased intracellular calcium and reactive oxygen species (Fig. 1 ).
NLRP3 inflammasome in bacterial infections
Several distinct mechanisms are proposed to underlie NLRP3 activation, including potassium efflux, 23 phagolysosomal destabilization 24 and mitochondrial reactive oxygen species burst. 25, 26 Many bacterial pathogens activate NLRP3 inflammasome by secreting pore-forming toxins. Staphylococcus aureus a-hemolysin, in combination with TLR2 stimulation by bacterial lipopeptides released during growth, activates the NLRP3 inflammasome. 27 Analysis of isogenic single-, double-and triple-mutant S. aureus strains defective in a-, b-, and/or c-hemolysins revealed a redundant role for hemolysins in NLRP3 activation. 27, 28 An in vitro model of S. aureus subcutaneous abscess demonstrated a critical role for apoptosis-associated speck-like protein containing a CARD (ASC) and interleukin-1b (IL-1b) signaling in neutrophil recruitment and infection control. 29, 30 The hemolysins HlyA and MARTX secreted by Vibrio cholerae activate NLRP3 in a redundant manner similar to that of S. aureus. 31 Furthermore, in vivo studies of mouse strains deficient in inflammasome components revealed that caspase-1 and ASC play a protective role against V. cholerae infections, but NLRP3 does not. 31 This suggests that multiple inflammasomes contribute to host defense against V. cholerae in vivo.
Streptococcus pneumoniae, which colonizes the upper respiratory tract, is a leading cause of pneumonia and meningitis. These bacteria activate NLRP3 through its secreted pore-forming toxin pneumolysin. 32, 33 In a Streptococcus pneumoniae lung-infection model, 32, 33 NLRP3 elicits a protective immune response, as Nlrp3 À/À mice have higher bacterial loads and greater mortality than do wild-type (WT) mice. In contrast, Nlrp3 À/À and ASC-deficient mice develop less brain inflammation and have better outcomes than do WT mice in a pneumococcal meningitis model. 34 The blockade of caspase-1-mediated signaling with a combined regimen of recombinant IL-1-receptor antagonist and IL-18-binding protein leads to considerable amelioration of disease severity and brain pathology, suggesting that impairing inflammasome activation is a practical strategy for treating pneumococcal meningitis. Several other bacterial toxins activate the NLRP3 inflammasome, including cholera toxin B, adenylcyclase toxin, 35 and the Clostridium difficile toxins A and B. 36 As these toxins have distinct mechanisms of action, it remains unclear how they mediate the activation of NLRP3 inflammasome. Activation by cholera toxin B depends on caspase-11, but activation by adenylcyclase toxin, C. difficile toxin B, or pore-forming toxins does not. 35 Notably, caspase-11 is dispensable for the activation of caspase-1 by most stimuli that activate NLRP3 inflammasome, but it plays a role in the induction of pyroptosis and release of DAMPs. 35 Some effector proteins in the type 3 secretion system activate NLRP3 inflammasome. For example, the Yersinia pestis subspecies KIM YopJ effector protein, 37 an acetyltransferase that causes apoptosis through inactivation of mitogen-activated protein kinases and IjB kinases, 38 activates the NLRP3 inflammasome. The role of NLRP3 activation in Y. pestis infection in vivo, however, remains to be explored.
Another study identified the role of interferon-inducible protein immunity-related GTPase family member b10 (IRGB10) in the activation of interferon regulatory factor 1-dependent AIM2 and caspase-11-dependent NLRP3 inflammasomes in response to bacterial infection. 39 IRGB10 directly targeted Gram-negative bacteria coated with guanylate-binding proteins. Guanylate-binding proteins mediate the entry of Gram-negative bacteria into the cytoplasm, where lipopolysaccharide binds and activates caspase-11. [40] [41] [42] Activated caspase-11 directly cleaves the propyroptotic factor gasdermin D, and the N-terminal fragment of gasdermin D then induces pyroptosis and activates the NLRP3 inflammasome. 43, 44 NLRP3 inflammasome in viral, fungal and parasitic infections
Several studies have reported a role for NLRP3 in the innate immune response to viruses. Initial studies demonstrated that NLRP3 inflammasome can be activated in vitro by Sendai virus, 21 influenza A virus 21, 45 and adenovirus. 46 Influenza A virus activates NLRP3 through its proton-selective M2 channel, 47 which elicits a protective host inflammatory response. 45, 48, 49 Recent studies have uncovered the role of a DNA sensor ZBP1/DAI (Z-DNA binding protein 1/DNA-dependent activator of interferon regulatory factors) in sensing influenza A virus, which may contribute to its inflammatory pathogenesis by NLRP3 inflammasome activation. 50, 51 Nlrp3
and Casp1 À/À mice exhibit increased mortality compared with WT mice but do not demonstrate defects in adaptive immunity to influenza..
45,49
Candida albicans, a fungus that can cause severe opportunistic infections in immunocompromised hosts, can activate NLRP3 inflammasomes. 52, 53 Experiments with C. albicans at various morphological stages, 54, 55 and with mutants that cannot form hyphae, revealed that the transition from yeast cells to hyphae is important for NLRP3 activation. 54 In vivo experiments with Tlr2
, Casp1 À/À and Il1r À/À mice demonstrated a protective role for NLRP3 inflammasome in a model of disseminated candidiasis. 55 Using a murine model of intranasal Aspergillus infection, a recent study characterized the combined role of multiple inflammasomes (NLRP3 and AIM2) in response to Aspergillus.
56 Deficiency of either NLRP3 or AIM2 resulted in minor reductions in survival and slightly enhanced fungal infection levels. However, deficiency of both NLRP3 and AIM2 resulted in a near complete loss of caspase-1 cleavage and IL-1b and IL-18 secretion. 56 This study provided the first mechanistic evidence of the concerted action of these two inflammasomes in providing protection against Aspergillus infection.
NLRP3 inflammasome is one of the major regulators of IL-1b and IL-18 in vitro and in vivo.
57 Lima-Junior et al. 58 demonstrated an important protective role for NLRP3 inflammasome during Leishmania amazonensis infection of resistant C57BL/6 mice. In vitro experiments have shown that most Leishmania spp., including L. amazonensis, Leishmania braziliensis and Leishmania mexicana, activate caspase-1 and produce IL-1b in an NLRP3 inflammasome-dependent manner. 58 Furthermore, Nlrp3
À/À and Casp1 À/À mice are all highly susceptible to L. amazonensis infection, compared with C57BL/6 WT control mice, signifying the importance of NLRP3 inflammasome in providing protection. Interestingly, a more recent report on the role of NLRP3 during Leishmania major infection in a susceptible BALB/c background showed a pathogenic role for this inflammasome. 59 Although BALB/c WT mice infected with L. major display severe footpad swelling and parasite burden, Nlrp3 À/À , Asc À/À and Casp1 À/À mice exhibit substantially reduced footpad swelling and parasite burden, implying a pathogenic role for NLRP3 inflammasome in a BALB/c background. 59 The transforming growth factor b-activated kinase 1 (TAK1) acts as a central regulator of NLRP3 inflammasome homeostasis. 60 Absence of TAK1 in macrophages induced spontaneous activation of the NLRP3 inflammasome without requiring the priming and activating signals, suggesting a distinctive role for TAK1 in maintaining NLRP3 inflammasome homeostasis. 60 However, it is unclear how aberrant NLRP3 activation contributes to this loss of myeloid cells and whether TAK1-driven NLRP3 activation in myeloid cells is sufficient to cause autoinflammatory diseases. Further research on TAK1-deficient mice that also lack NLRP3 should provide more information.
NLRP3 inflammasome and tumorigenesis
In the nineteenth century, Rudolf Virchow's observations indicated a link between inflammation and cancer and suggested that immune and inflammatory cells are frequently present within tumors. 61 Indeed, chronic inflammation plays critical roles at multiple stages of cancer development and progression. [61] [62] [63] TLRs are the most widely studied PRRs in the pathogenesis of immune diseases and cancer; hence, TLRs are attractive targets for novel therapeutic agents. 6, 64 Emerging evidence suggests that other PRRs also function in inflammation and cancer.
NLRP3 inflammasome activation can play a dual role in cancer, as it does in inflammation. NLRP3 polymorphisms are associated with melanoma susceptibility, 65 colorectal cancer prognosis, [66] [67] [68] and the overall survival of patients with myeloma. 69 A Swedish case-control study revealed that the NLRP3 variant rs35829419 occurs more commonly in male patients and is strongly associated with nodular melanoma. 65 In mouse models of sarcoma and metastatic melanoma, NLRP3 activation is required to suppress natural killer cell-mediated and Tcell-mediated antitumor activity and to promote infiltration of myeloid-derived suppressor cells (MDSCs) and regulatory T cells. 70, 71 Specifically, NLRP3 silencing resulted in a fivefold reduction in the number of tumorassociated MDSCs in host mice, and NLRP3 À/À MDSCs reached tumor sites less efficiently than did WT MDSCs, thereby demonstrating a critical function of NLRP3 in mitigating tumorigenesis by modulating host immunity. 66, 71 Furthermore, in an orthotopic transplant mouse model of mammary adenocarcinoma, NLRP3 deficiency results in fewer pulmonary metastases. 72 The chemotherapeutic agents gemcitabine and 5-fluorouracil activate the NLRP3 inflammasome in MDSCs, which leads to IL-1b production that induces IL-17 secretion from CD4 + T cells, blunting the effectiveness of the anticancer drugs. 73 Accordingly, gemcitabine and 5-fluorouracil exhibit increased antitumor effects in Nlrp3 À/À or Caspase1 À/À mice, indicating that chemotherapy-mediated activation of NLRP3 is a positive regulator of cancer growth. 73 Together, these findings suggest that NLRP3 plays a protumorigenic role in cancer. Despite evidence indicating that NLRP3 has a protumorigenic function, it may also suppress tumorigenesis.
Nlrp3
À/À mice are more susceptible to colon cancer, develop more colon polyps in the azoxymethane-dextran sodium sulfate (AOM-DSS) mouse model, and exhibit accelerated tumor growth accompanied by drastically low levels of colonic IL-18 in a carcinogenesis model. These findings suggest that NLRP3 protects against neoplasia formation, and IL-18 is closely associated with colon cancer initiation. 66, 74 Notably, Il18 À/À mice generate more tumors than do controls after treatment with AOM-DSS, whereas injection of recombinant IL-18 successfully restrains disease progression, which may be associated with the MyD88-related pathway. 75 NLRP3 plays a similar antitumorigenic role in hepatocellular carcinoma. Both mRNA and protein levels of NLRP3 are markedly downregulated in hepatic parenchymal cells derived from liver cancer biopsies, as compared with non-cancerous samples. 76 Therefore, NLRP3 can promote tumor cell survival by activating the nuclear factor-jB-signal transducer and activator of transcription-1/3 pathway or by limiting cytotoxic immune cell infiltration, but it can also suppress malignant progression by triggering the mitochondrial apoptotic pathway or enhancing immune-cytokine levels in the tumor microenvironment. In addition, the role of NLRP3 in tumorigenesis may be tissue-or cell-dependent. For example, NLRP3 exhibits a protective role against colon cancer but a procarcinogenic role in gastric and prostate cancers. 77 Therefore, a comprehensive analysis of NLRP3 using conditional knockout models and pharmacological activators or inhibitors is needed to decode the precise mechanisms of NLRP3 activity in cancer. cell-mediated responses in carcinogen-induced tumors. 68, 70 However, excessive or inappropriate activation of NLRP3 inflammasome is implicated in the pathogenesis of inherited and acquired inflammatory diseases, leading to increased inflammatory responses in lung metastases and suppression of antitumor immunity in certain conditions. 79 The NLRP3 inflammasome also plays an important role in the development and progression of gastrointestinal cancer, skin cancer, breast cancer and hepatocellular carcinoma. 80 Furthermore, the overexpressed and constitutively activated NLRP3 inflammasome contributes to the progression of late-stage melanoma, 81 whereas it is considerably down-regulated in human hepatocellular carcinoma. 82 A crucial role of the NLRP3 inflammasome in regulating gut homeostasis is strengthened by recent studies examining the molecular mechanisms in which NLRP3, ASC and caspase-1 control the integrity of the intestinal epithelium and modulate immune responses to the gut microbiota during experimental colitis. In addition to increased transmural permeability, the colonic crypts of Nlrp3 À/À mice exert reduced antimicrobial activity, which is associated with altered expression of colonic defensins. 66, 83 Defensins comprise a family of short peptides with bactericidal activity, and their secretion by colonic crypt cells represents an important mechanism for guarding the homeostasis of the intestinal epithelium. This is illustrated by the observation that diminished expression of these antimicrobial compounds also occurs in patients with Crohn disease. 84, 85 Whether the NLRP3 inflammasome modulates defensin expression directly or downstream of IL-1b and/or IL-18 secretion remains to be determined. Nevertheless, these observations indicate a key role for NLRP3 inflammasome in protection against colitis.
Because NLRP3 is expressed in both immune and epithelial cells, 86 bone marrow chimera mice were used to determine the cellular compartments contributing to NLRP3 inflammasome-mediated protection against colitis. NLRP3 signaling is essential in non-hematopoietic cells because expression of NLRP3 66 and caspase-1 74 in these cells prevents the aggravated disease symptoms caused by AOM-DSS treatment in Nlrp3 À/À and Caspase1 À/À mice. This effect most likely originates from intestinal epithelial cells because activation of inflammatory and repair-signaling pathways in these cells protects against colitis. 87, 88 However, NLRP3 inflammasome signaling in epithelial cells does not indicate that its activation in myeloid cells does not contribute to protection against colitis. Indeed, reconstituting Nlrp3 À/À mice with WT bone marrow confers resistance against colon tumorigenesis in the chronic AOM-DSS model. 66, 68 This suggests that NLRP3 inflammasome activity in radiosensitive cells of the lamina propria also helps to protect against chronic colitis. Therefore, depending on spatiotemporal parameters, inflammasome activation in the cells of the epithelial layer and the lamina propria most likely contribute to the homeostasis of the gut epithelium and protection against colitis. In support of this model, colitis-associated tumorigenesis is more severe in Caspase1 À/À mice than in mice lacking caspase-1 in either the epithelial or myeloid compartments. 89 
Inhibitors targeting NLRP3 inflammasome complexes
Recent studies have identified several diverse compounds that can influence NLRP3 inflammasome activation and modulate disease pathogenicity ( Table 2 ). The type 2 diabetes drug glyburide prevents the activation of the NLRP3 inflammasome. 90 Glyburide's cyclohexylurea group, which binds to ATP-sensitive potassium channels for insulin secretion, is dispensable for inflammasome inhibition. 90 The NLRP3 inhibitor MCC950 inhibits the autoactivation of the inflammasome caused by mutated NLRP3 and blocks the formation of NLRP3-induced ASC specks, which are not observed with other inflammasome stimuli. 91 In addition, MCC950 effectively ameliorates the pathologic responses to experimental autoimmune encephalomyelitis and improves the survival rate in a mouse model of cryopyrin-associated periodic fever syndrome. This suggests that MCC950 could have a potential therapeutic effect in patients with NLRP3-associated inflammatory or autoimmune diseases. 91 Cinnamaldehyde and allopurinol, which possess antioxidative and antiinflammatory activities, relieve cardiac inflammation and fibrosis in fructose-induced cardiac injury related to NLRP3 inflammasome activation. 92 The widely used antidiabetic drug metformin and the sirtuin 1 activator resveratrol prevent endoplasmic reticulum stress-associated NLRP3 inflammasome activation in adipose tissue of diabetic mice. 93 Withaferin A, a withanolide purified from Withania somnifera (or Indian ginseng plant), inhibits Helicobacter pylori-induced production of IL-1b in dendritic cells by regulating nuclear factor-jB and NLRP3 inflammasome activation. 94 Fluoxetine, a widely used antidepressant, substantially suppresses NLRP3-signaling pathways in macrophages and microglia, 95 suggesting that NLRP3 is a promising therapeutic target for treating inflammasome-associated depression. Isoliquiritigenin, a flavonoid derived from Glycyrrhiza uralensis (or Chinese licorice plant), inhibits diet-induced obesity, insulin resistance and adipose tissue inflammation by suppressing NLRP3 inflammasome activation. 96 
Conclusion
Remarkable advancements in recent years have greatly increased our understanding of NLRP3 function and its ª 2019 John Wiley & Sons Ltd, Immunology, 156, 329-338 regulation in host defense and disease pathogenesis. The NLRP3 inflammasome is important not only for fighting against bacterial, fungal and viral infections but also for mediating cancer initiation and progression. NLRP3 inflammasome activation can create a pro-inflammatory microenvironment that induces malignant transformation and suppresses local immunity normally provided by NK or T cells. In addition, chemotherapeutic agents can activate the inflammasome, which supports cancer growth via positive feedback. Accumulating evidence has identified various compounds that influence the activation of the NLRP3 inflammasome to modulate inflammatory disease pathogenicity. Moreover, inflammasome-related autophagy may also contribute to metastasis and anticancer drug resistance. These findings greatly highlight NLRP3 inflammasome as a novel target to prevent and treat cancer.
Despite mounting evidence that inflammasomes mediate cancer prevention, contrary data also exist. To this end, numerous questions remain unanswered. Is inflammasome-related carcinogenesis cell-or tissue-dependent? Do specific NLRs exhibit different bioactivities that are correlated with specific cancer stages? Twenty-two NLR family members are present in humans, and it is unclear how these diverse molecules are activated or how they interact with each other. This complex network is awaiting elucidation. Identifying novel receptor-binding molecules, signaling pathways and targets for cancer prevention or therapy is another important endeavor for future research. Inflammasomes are becoming a noteworthy research topic in the tumor microenvironment field, and the likelihood that they will be developed as important biomarkers for cancer diagnosis or prognosis is quite high. Given the emerging role of NLRP3 in a diverse range of cancers, the discovery of effective therapeutics that selectively target the NLRP3 inflammasome activation pathway and thereby control tumor formation and progression is of considerable interest. 
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